Forbes: Biosimilar Competition Will Lower Consumer Prices

When it comes to drug prices, what’s dominating the headlines is bad news story after bad news story. Turing Pharmaceuticals raised the price of an old AIDS drug by more than 5,000 percent overnight, and Valeant Pharmaceuticals International raised a blood pressure drug price by nearly 3,000 percent since 2013, among other consumer losing examples. […]

Prescription Drug Competition Means Savings

REAL CLEAR POLICY: Competition for some of the priciest drugs may soon be coming to a pharmacy near you. The new development has to do with “biologics,” which are drugs produced in living systems such as plant and animal cells or microorganisms. To Continue Reading, visit Real Clear Policy

ConsumerGram: Patient Benefits from Biosimilar Competition

The recent approval of the first biosimilar drug by the FDA will mark the beginning of competition for a class of lifesaving medicines in the U.S., after nearly a decade of availability in Europe and elsewhere.  This ConsumerGram will explore how the pending introduction of competition for biologic drugs will lead to immense consumer benefits, both […]

ACI Capitol Hill Event Highlights Benefits of Biosimilars Competition for Patients and Taxpayers

WASHINGTON, Dec. 9, 2014 /PRNewswire-USNewswire/ — The American Consumer Institute Center for Citizen Research (ACI) today hosted an event on Capitol Hill bringing together a panel of experts highlighting the dramatic benefits that unimpeded biosimilars competition would mean for both patients and taxpayers. The event was held as the Food and Drug Administration (FDA) is […]

More Price Regulations = More Costs for Consumers

Becki Gray of the John Locke Institute, the leading think tank in North Carolina, just posted an interesting piece that discusses an analysis that ACI did some years ago.  The analysis shows that as automobile insurance price regulation increases so do the costs that consumers pay.  That irony should give us pause and resolve in knowing […]

ACI in Forbes: FDA Action Can Save Lives, Money

Dr. Joseph Fuhr, Jr., professor of Economics and a senior fellow at ACI, wrote a piece on how biosimilar competition could provide wider choice and cheaper access to lifesaving drugs for patients, but the FDA needs to write the rules necessary to permit competitive entry. His piece is available to read and print at Forbes.

ACI in the Huffington Post: FDA Delays Will Cost Money and Lives

This article, written by ACI president Steve Pociask, discusses the benefits of biosimilar dugs.  These drugs are generic-like versions of lifesaving brand named biopharmaceutical drugs, called biologics.  Europe has had biosimilar competition since 2006, but the U.S. has yet to approve a single biosimilar drug for U.S. patients.  The article calls on the FDA to accelerate its rulemaking and write […]

Making the Case for Biosimilars: ACI in the Hill’s Congressional Blog

Lower Prices and Greater Access to Life-Saving Drugs Generic drugs have saved over a trillion dollars in healthcare costs between 2002 and 2011 by competing against name brand drugs.  Another opportunity now exists to further reduce pharmaceutical drug expenditures involving a growing, but expensive, innovative class of drugs, called biologics. The introduction of their generic-like […]

New ConsumerGram: Lifesaving Drugs at Lower Costs

The Food and Drug Administration (FDA) began approving generic (unbranded) prescription drugs around 30 years ago, and generic drugs are now saving consumers more than one trillion dollars per decade in healthcare costs over their brand named counterparts.  Competition from generics has provided more options to doctors and better access to patients – at prices […]